📄 APNIMED, INC. ($APMD)

Apnimed is a late-stage clinical pharmaceutical company focused on developing novel oral therapies for sleep-related breathing diseases. Its sole product candidate, AD109 (Oxnimbi), is an investigational combination drug for the treatment of obstructive sleep apnea (OSA) designed to improve upper airway muscle activity. The company submitted a New Drug Application (NDA) for Oxnimbi to the FDA in April 2026, which was accepted for review in July 2026. Offering: $150.0M at $150.0M valuation Proceeds: Approximately $228.8 million to fund the regulatory approval process and, if approved, the commercial launch for Oxnimbi for the treatment of OSA., The remaining proceeds to fund research and development activities for additional product candidates, working capital, and other general corporate purposes.

Apnimed is a late-stage clinical pharmaceutical company focused on developing novel oral therapies for sleep-related breathing diseases. Its sole product candidate, AD109 (Oxnimbi), is an investigational combination drug for the treatment of obstructive sleep apnea (OSA) designed to improve upper airway muscle activity. The company submitted a New Drug Application (NDA) for Oxnimbi to the FDA in April 2026, which was accepted for review in July 2026.